SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-20-042521
Filing Date
2020-09-03
Accepted
2020-09-03 16:19:46
Documents
63
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q inzy-10q_20200630.htm 10-Q 2633245
2 EX-31.1 inzy-ex311_116.htm EX-31.1 19440
3 EX-31.2 inzy-ex312_119.htm EX-31.2 19454
4 EX-32.1 inzy-ex321_118.htm EX-32.1 9801
5 EX-32.2 inzy-ex322_117.htm EX-32.2 9853
  Complete submission text file 0001564590-20-042521.txt   7930643

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT inzy-20200630.xml EX-101.INS 1669257
7 XBRL TAXONOMY EXTENSION SCHEMA inzy-20200630.xsd EX-101.SCH 41823
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE inzy-20200630_cal.xml EX-101.CAL 38843
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE inzy-20200630_def.xml EX-101.DEF 159675
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE inzy-20200630_lab.xml EX-101.LAB 371560
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE inzy-20200630_pre.xml EX-101.PRE 292490
Mailing Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210
Business Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210 857-330-4340
Inozyme Pharma, Inc. (Filer) CIK: 0001693011 (see all company filings)

IRS No.: 475129768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39397 | Film No.: 201159478
SIC: 2834 Pharmaceutical Preparations